Translational data analyses
Ariana offers innovative data analytics services in translational medicine for the identification of new targets and the development of new therapeutic compounds or diagnostic products. Ariana’s expertise in data mining and statistical methods applied to high-dimensional and heterogeneous data as well as its technologic platform KEM® help identify new associations of features in a ‘without a priori’ approach and generate new hypotheses.
Ariana’s expertise lies in combining data and knowledge extracted from preclinical, clinical and epidemiological data bases. Our technology helps improve the design of clinical trials to demonstrate real life clinical impact and hence, enable market access and reimbursement procurement.
Ariana® Pharma is a leading digital health company focused on developing advanced decision support systems and computational solutions for personalized medicine. Its therapeutic decision support tools and its proprietary data mining platform KEM® (Knowledge Extraction and Management) enable clinicians choose optimal therapeutic solutions and pharmaceutical partners to develop novel targeted therapies for cancer patients.
Ariana is currently developing a set of software combined with laboratory tests that enable personalized treatment selection in oncology. Ariana has also developed algorithms that have been embedded in personalized medicine diagnostic tools. Ariana conducts these projects through partnerships with pharmaceutical and diagnostic companies as well as academic partners.
Ariana’s technology and expertise are also offered through consulting and data analysis services as well as licensing agreements for the KEM® software suite. Ariana’s team is multidisciplinary and highly experienced with degrees in Medicine, Computational Biology, Biostatistics, Biomathematics and Artificial Intelligence. Founded in 2003 as a spin-off of Institut Pasteur, Ariana is based in Paris and has a fully owned subsidiary in the U.S. It has entered into a distribution agreement with a Japanese provider, CT-LS.
Ariana is currently developing a set of software combined with laboratory tests that enable personalized treatment selection in oncology. Ariana has also developed algorithms that have been embedded in personalized medicine diagnostic tools. Ariana conducts these projects through partnerships with pharmaceutical and diagnostic companies as well as academic partners.
Ariana’s technology and expertise are also offered through consulting and data analysis services as well as licensing agreements for the KEM® software suite. Ariana’s team is multidisciplinary and highly experienced with degrees in Medicine, Computational Biology, Biostatistics, Biomathematics and Artificial Intelligence. Founded in 2003 as a spin-off of Institut Pasteur, Ariana is based in Paris and has a fully owned subsidiary in the U.S. It has entered into a distribution agreement with a Japanese provider, CT-LS.
Ariana’s main role in IMODI is to develop and deploy a decision support system enabling oncologists to select a personalized treatment strategy for patient care by systematically combining a large variety of data generated through the project (clinical, biochemical and molecular data).
Additionally, analyses performed by Ariana will offer a better understanding of the molecular mechanisms underlying the therapeutic compounds action and will facilitate an efficient and rapid development of new targeted therapies.
Contact USA:
Dan Manak
- 28 rue du Docteur Finlay 75015 Paris France